Adam Hoffman
It is becoming more and clearer in neurology how important is neuroinflammation. Numerous non-inflammatory neurological conditions, including stroke, epilepsy, and cancer, as well as neuroinflammatory diseases like multiple sclerosis have been linked to neuroinflammation. The presence of CNS resident cells, mostly glial cells like microglia and the CNS resident macrophages is necessary for the immune response within the brain. To create a less hemolytic peptide with anti-neuroinflammatory, antibacterial, and cytotoxic effects against tumor cells, we examined the peptide Ca-MAP1, which was bioinspired on the immature cytolytic toxin of C. Albicans called candidalysin. Studies were carried out in vitro and silico at varying doses. Ca-MAP1 was not cytotoxic to MRC-5 and BV-2 cells and only displayed weak hemolytic activity at low concentrations. Acinetobacter baumannii, Escherichia coli ATCC, E. coli KPC, Klebsiella pneumoniae ATCC, Pseudomonas aeruginosa, and Staphylococcus aureus ATCC were all susceptible to Ca-MAP1. Furthermore, Ca-MAP1 inhibits the generation of nitrate by 93.78% at 18.1 M in the BV-2 microglia model, demonstrating antineuroinflammatory action. With an IC50 of 38.4 M, CaMAP1 has cytotoxic action against the tumor cell line NCI-H292 at a concentration of 36.3 M. CaMAP1 exhibits outcomes that need evaluation in the following stages to support the control of infections and offer an alternative anticancer therapy